Results 1 to 10 of about 49,428 (256)
Antibody drug conjugates [PDF]
Indian Journal of Medical and Paediatric Oncology, 2020 Antibody drug conjugates (ADCs) are chemically engineered drugs consisting of monoclonal antibody (mAb) and cytotoxic compound attached chemically by a linker. Upon attachment to a specific target antigen, ADC enters into the cell and payload is released,
Stalin Bala, Siva K Prasad
doaj +2 more sources
Introduction to Antibody-Drug Conjugates [PDF]
Antibodies, 2021 Antibody-drug conjugates (ADCs) are innovative biopharmaceutical products in which a monoclonal antibody is linked to a small molecule drug with a stable linker.
Mark C. Pettinato
doaj +3 more sources
Antibody–drug conjugates [PDF]
Nature Reviews Drug Discovery, 2013 Ideally, targeted therapies attack diseased cells while leaving healthy ones alone. It’s a strategy that could result in more effective treatments for cancer (or other diseases) with fewer toxic side effects than traditional chemotherapies. A burgeoning class of targeted therapies, called antibody–drug conjugates (ADC), deliver dual therapies in a ...
Ryan P Million
exaly +6 more sources
Clinical application and optimization strategies for antibody–drug conjugates in solid tumors [PDF]
Journal of International Medical ResearchDespite the availability of multiple treatments for solid tumors, the prognosis of advanced solid tumors remains poor. Antibody–drug conjugates, a novel type of antitumor drugs, which are created by conjugating cytotoxic small-molecule drugs with ...
Jie Qu +7 more
doaj +2 more sources
Antibody–Drug Conjugates for Cancer Therapy [PDF]
Molecules, 2020 Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload.
Umbreen Hafeez +3 more
doaj +4 more sources
Antibody drug conjugates in the clinic
Bioengineering & Translational MedicineAntibody‐drug conjugates (ADCs), chemotherapeutic agents conjugated to an antibody to enhance their targeted delivery to tumors, represent a significant advancement in cancer therapy.
Edidiong Udofa +3 more
doaj +3 more sources
Antibody-Drug Conjugates [PDF]
Pharmaceutical Research, 2015 Antibody-drug conjugates (ADCs) are an exciting and new class of therapeutic modalities that have gained significant traction over the past few years – specifically in the field of oncology. With the recent approvals of CD-30 directed Adcetris® (brentuximab vedotin) and the Her2 targeted Kadcyla® (ado-trastuzumab emtansine) and hundreds of other ADCs ...
Ashutosh A, Kulkarni +1 more
openaire +5 more sources
Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates [PDF]
Journal of Clinical Medicine, 2021 A summary of the key technological advancements in the preparation of antibody–oligonucleotide conjugates (AOCs) and the distinct advantages and disadvantages of AOCs as novel therapeutics are presented. The merits and demerits of the different approaches to conjugating oligonucleotides to antibodies, antibody fragments or other proteins, mainly from ...
Julien Dugal-Tessier +2 more
openaire +2 more sources
Pharmaceutics, 2023 Typically, antibody–drug conjugates (ADCs) are made up of a humanized antibody and a small-molecule medication connected by a chemical linker. ADCs’ ability to deliver cytotoxic agents to the specific site with reduced side effects showed promising ...
Lal Bahadur Pal +3 more
doaj +1 more source
Therapeutic Roles of Antibody Drug Conjugates (ADCs) in Relapsed/Refractory Lymphomas
Hematology/Oncology and Stem Cell Therapy, 2023 Relapsed or refractory lymphoma is commonly treated with combination chemoimmunotherapy and cellular immunotherapy. Modest response rates and associated toxicities are obstacles to achieving durable remission using traditional cytotoxic chemotherapy ...
Hamza Hashmi +2 more
doaj +1 more source